🔴 AIM ImmunoTech is trading 5% down in pre-market as no clear company-specific catalyst was identified

AIM ImmunoTech is trading 5.15% down at $0.21 after no clear company-specific catalyst was identified for September 18, 2026.

• Recent disclosures include a September 9 CEO Corner update and a September 3 debt-to-equity conversion, but neither directly explains the pre-market decline.
• The broader market is modestly higher, making market-wide sentiment an unlikely explanation.
• The move may reflect low-liquidity trading or lingering dilution concerns.